Hims & Hers Health (NYSE:HIMS) Trading 9.3% Higher - Here's Why

Key Points

• Hims & Hers Health shares rose 9.3% to close at $55.03, despite experiencing a 55% drop in trading volume compared to average sessions.
• Analysts have mixed ratings for the stock, with a "buy" target set at $68.00 by Canaccord Genuity, while the average target price is $38.92.
• Insider trading activity has been significant, with CEO Andrew Dudum selling over 128,000 shares recently, reflecting a decline in his holdings by 44.40%.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price traded up 9.3% on Thursday . The stock traded as high as $54.77 and last traded at $55.03. 14,883,199 shares were traded during trading, a decline of 55% from the average session volume of 33,064,449 shares. The stock had previously closed at $50.35.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Zacks Research downgraded Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Truist Financial reduced their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research report on Monday, August 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Finally, Morgan Stanley reissued an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Performance

The company has a market cap of $13.06 billion, a price-to-earnings ratio of 72.21, a P/E/G ratio of 3.91 and a beta of 2.14. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock's fifty day simple moving average is $50.71 and its 200 day simple moving average is $45.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm's revenue was up 72.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Michael Chi sold 13,749 shares of the stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $694,324.50. Following the completion of the sale, the insider owned 297,139 shares of the company's stock, valued at $15,005,519.50. This represents a 4.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Irene Becklund sold 8,410 shares of the stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $424,705.00. Following the transaction, the insider directly owned 1,418 shares of the company's stock, valued at $71,609. The trade was a 85.57% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,511,978 shares of company stock worth $76,944,116. 13.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after acquiring an additional 227 shares during the period. Bessemer Group Inc. increased its stake in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company's stock worth $30,000 after acquiring an additional 312 shares during the period. True Vision MN LLC increased its stake in shares of Hims & Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after acquiring an additional 328 shares during the period. Allworth Financial LP increased its stake in shares of Hims & Hers Health by 20.0% during the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after acquiring an additional 334 shares during the period. Finally, Signaturefd LLC increased its stake in shares of Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after acquiring an additional 388 shares during the period. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.